Table 9.
Ongoing studies of prophylactic treatments and vaccine candidates against hRSV.
| Prophylactic Approach | Type | Name | Current Clinical Trials | NCT Number | References |
|---|---|---|---|---|---|
| Monoclonal Antibodies | Targeting F protein | Palivizumab | Market-approved | n.a. | [304,306,307,321,322] |
| Motavizumab | Completed Phase 3 | NCT00121108 | [310,311,312] | ||
| NCT00129766 | |||||
| MEDI8897 | Ongoing Phase 3 | NCT03959488 | [313,314] | ||
| Targeting N protein | Monoclonal anti-N antibody | Preclinical studies only | n.a. | [16] | |
| Vaccine Candidates | Live-attenuated | RSV LID cpΔM2-2 | Completed Phase 1 | NCT02890381 | [316] |
| NCT02948127 | |||||
| RSV LID ΔM2-2 1030s | Completed Phase 1 | NCT02952339 | [323] | ||
| RSV D46/NS2/N/ΔM2-2-HindIII | Completed Phase 1 | NCT03099291 | [324] | ||
| NCT03102034 | |||||
| RSV-ΔNS2 Δ1313/I1314L | Ongoing Phase 1 |
NCT01893554 NCT03227029 |
[317,318] | ||
| SeVRSV | Ongoing Phase 1 | NCT03473002 | [325,326] | ||
| Live-attenuated/Chimeric | rBCG-N-hRSV | Ongoing Phase 1 | NCT03213405 | [319,320] | |
| Vector | VXA-RSVf | Ongoing Phase 1 | NCT02830932 | [16] | |
| MVA-BN-RSV | Ongoing Phase 2 | NCT02873286 | [327] | ||
| ChAd155-RSV | Ongoing Phase 1 | NCT03636906 | [328] | ||
| Ongoing Phase 2 | NCT02927873 | ||||
| Ad26.RSV.PreF | Completed Phase 2 | NCT03334695 | [329] | ||
| Ongoing Phase 2 | NCT03982199 | ||||
| Particle | RSV F Nanoparticle | Completed Phase 1 (pediatric) | NCT02296463 | [330,331,332] | |
| Completed Phase 3 (elderly) | NCT02608502 | ||||
| Completed Phase 3 (maternal) | NCT02624947 | ||||
| Subunit | DPX-RSV-SHe | Completed Phase 1 | NCT02472548 | [333] | |
| RSV F DS-Cav1 | Completed Phase 1 | NCT03049488 | [334,335,336] | ||
| GSK RSV F | Completed Phase 2 | NCT02360475 | [337] | ||
| NCT02753413 | |||||
| NCT02956837 | |||||
| RSV F subunit vaccine (Pfizer) | Ongoing Phase 2 | NCT03529773 | [16] |